Literature DB >> 15791890

Treatment of vertigo.

Randy Swartz1, Paxton Longwell.   

Abstract

Vertigo is the illusion of motion, usually rotational motion. As patients age, vertigo becomes an increasingly common presenting complaint. The most common causes of this condition are benign paroxysmal positional vertigo, acute vestibular neuronitis or labyrinthitis, Ménière's disease, migraine, and anxiety disorders. Less common causes include vertebrobasilar ischemia and retrocochlear tumors. The distinction between peripheral and central vertigo usually can be made clinically and guides management decisions. Most patients with vertigo do not require extensive diagnostic testing and can be treated in the primary care setting. Benign paroxysmal positional vertigo usually improves with a canalith repositioning procedure. Acute vestibular neuronitis or labyrinthitis improves with initial stabilizing measures and a vestibular suppressant medication, followed by vestibular rehabilitation exercises. Meniere's disease often responds to the combination of a low-salt diet and diuretics. Vertiginous migraine headaches generally improve with dietary changes, a tricyclic antidepressant, and a beta blocker or calcium channel blocker. Vertigo associated with anxiety usually responds to a selective serotonin reuptake inhibitor.

Entities:  

Mesh:

Year:  2005        PMID: 15791890

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  14 in total

1.  Predictive capability of historical data for diagnosis of dizziness.

Authors:  Jeff G Zhao; Jay F Piccirillo; Edward L Spitznagel; Dorina Kallogjeri; Joel A Goebel
Journal:  Otol Neurotol       Date:  2011-02       Impact factor: 2.311

2.  Effect of the novel histamine H4 receptor antagonist SENS-111 on spontaneous nystagmus in a rat model of acute unilateral vestibular loss.

Authors:  Mathieu Petremann; Cindy Gueguen; Viviana Delgado Betancourt; Eric Wersinger; Jonas Dyhrfjeld-Johnsen
Journal:  Br J Pharmacol       Date:  2019-08-28       Impact factor: 8.739

3.  Chiropractic management of a 40-year-old female patient with Ménière disease.

Authors:  Peter C Emary
Journal:  J Chiropr Med       Date:  2010-03

Review 4.  Principles of vestibular physical therapy rehabilitation.

Authors:  Susan L Whitney; Patrick J Sparto
Journal:  NeuroRehabilitation       Date:  2011       Impact factor: 2.138

Review 5.  Management of vestibular schwannoma: focus on vertigo.

Authors:  Manisha Dayal; Angelica Perez-Andujar; Cynthia Chuang; Andrew T Parsa; Igor J Barani
Journal:  CNS Oncol       Date:  2013-01

6.  Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms.

Authors:  Fulvio Plescia; Pietro Salvago; Francesco Dispenza; Giuseppe Messina; Emanuele Cannizzaro; Francesco Martines
Journal:  Int J Environ Res Public Health       Date:  2021-04-30       Impact factor: 3.390

7.  Predictive Capability of an iPad-Based Medical Device (medx) for the Diagnosis of Vertigo and Dizziness.

Authors:  Katharina Feil; Regina Feuerecker; Nicolina Goldschagg; Ralf Strobl; Thomas Brandt; Albrecht von Müller; Eva Grill; Michael Strupp
Journal:  Front Neurol       Date:  2018-02-27       Impact factor: 4.003

8.  An evaluation of the cost-effectiveness of booklet-based self-management of dizziness in primary care, with and without expert telephone support.

Authors:  Lucy Yardley; Sarah Kirby; Fiona Barker; Paul Little; James Raftery; Debbie King; Anna Morris; Mark Mullee
Journal:  BMC Ear Nose Throat Disord       Date:  2009-12-29

9.  Comparison of the Risk for Peripheral Vertigo between Physicians and the General Population.

Authors:  Wei-Ta Huang; Hung-Jung Lin; I-Jung Feng; Chien-Chin Hsu; Jhi-Joung Wang; Chien-Cheng Huang; Shih-Bin Su
Journal:  Iran J Public Health       Date:  2021-01       Impact factor: 1.429

10.  Clinical and Demographic Features of Vertigo: Findings from the REVERT Registry.

Authors:  Sam Agus; Heike Benecke; Cornelia Thum; Michael Strupp
Journal:  Front Neurol       Date:  2013-05-10       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.